Glycogen storage disease type III

Glycogen storage disease type III (also known as GSDIII or Cori disease) is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body’s cells. The accumulated glycogen is structurally abnormal and impairs the function of certain organs and tissues, especially the liver and muscles.

GSDIII is divided into types IIIa, IIIb, IIIc, and IIId, which are distinguished by their pattern of signs and symptoms. GSD types IIIa and IIIc mainly affect the liver and muscles, and GSD types IIIb and IIId typically affect only the liver. It is very difficult to distinguish between the types of GSDIII that affect the same tissues. GSD types IIIa and IIIb are the most common forms of this condition.

Beginning in infancy, individuals with any type of GSDIII may have low blood sugar (hypoglycemia), excess amounts of fats in the blood (hyperlipidemia), and elevated blood levels of liver enzymes. As they get older, children with this condition typically develop an enlarged liver (hepatomegaly). Liver size usually returns to normal during adolescence, but some affected individuals develop chronic liver disease (cirrhosis) and liver failure later in life. People with GSDIII often have slow growth because of their liver problems, which can lead to short stature. In a small percentage of people with GSDIII, noncancerous (benign) tumors called adenomas may form in the liver.

Individuals with GSDIIIa may develop muscle weakness (myopathy) later in life. These muscle problems can affect both heart (cardiac) muscle and the muscles that are used for movement (skeletal muscles). Muscle involvement varies greatly among affected individuals. The first signs and symptoms are typically poor muscle tone (hypotonia) and mild myopathy in early childhood. The myopathy may become severe by early to mid-adulthood. Some people with GSDIIIa have a weakened heart muscle (cardiomyopathy), but affected individuals usually do not experience heart failure. Other people affected with GSDIIIa have no cardiac muscle problems.

Frequency

The incidence of GSDIII in the United States is 1 in 100,000 individuals. This condition is seen more frequently in people of North African Jewish ancestry; in this population, 1 in 5,400 individuals are estimated to be affected.

GSDIIIa is the most common form of GSDIII, accounting for about 85 percent of all cases. GSDIIIb accounts for about 15 percent of cases. GSD types IIIc and IIId are very rare, and their signs and symptoms are poorly defined. Only a small number of affected individuals have been suspected to have GSD types IIIc and IIId.
Causes
Mutations in the AGL gene cause GSDIII. The AGL gene provides instructions for making the glycogen debranching enzyme. This enzyme is involved in the breakdown of glycogen, which is a major source of stored energy in the body. Between meals the body breaks down stores of energy, such as glycogen, to use for fuel.

Most AGL gene mutations lead to the production of a nonfunctional glycogen debranching enzyme. These mutations typically cause GSD types IIIa and IIIb. The mutations that cause GSD types IIIc and IIId are thought to lead to the production of an enzyme with reduced function. All AGL gene mutations lead to storage of abnormal, partially broken down glycogen molecules within cells. A buildup of abnormal glycogen damages organs and tissues throughout the body, particularly the liver and muscles, leading to the signs and symptoms of GSDIII.

Inheritance Pattern
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition
- AGL deficiency
- Cori disease
- Cori’s disease
- debrancher deficiency
- Forbes disease
- glycogen debrancher deficiency
- GSD III
- GSD3
- limit dextrinosis

Diagnosis & Management
Genetic Testing Information
- What is genetic testing? /primer/testing/genetictesting
Research Studies from ClinicalTrials.gov

- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22glycogen+storage+disease+type+III%22+OR+%22Glycogen+Storage+Disease+Type+III%22

Other Diagnosis and Management Resources

- GeneReview: Glycogen Storage Disease Type III
  https://www.ncbi.nlm.nih.gov/books/NBK26372

Additional Information & Resources

Health Information from MedlinePlus

- Encyclopedia: Hepatomegaly
  https://medlineplus.gov/ency/article/003275.htm
- Health Topic: Carbohydrate Metabolism Disorders
  https://medlineplus.gov/carbohydratemetabolismdisorders.html
- Health Topic: Cardiomyopathy
  https://medlineplus.gov/cardomyopathy.html
- Health Topic: Cirrhosis
  https://medlineplus.gov/cirrhosis.html
- Health Topic: Liver Diseases
  https://medlineplus.gov/liverdiseases.html
- Health Topic: Muscle Disorders
  https://medlineplus.gov/muscledisorders.html

Genetic and Rare Diseases Information Center

- Glycogen storage disease type 3
  https://rarediseases.info.nih.gov/diseases/9442/glycogen-storage-disease-type-3

Educational Resources

- Cincinnati Children’s Hospital: Glycogen Storage Disease
  https://www.cincinnatichildrens.org/health/g/gsd
- Merck Manual Consumer Version: Overview of Hereditary Metabolic Disorders
- Orphanet: Glycogen storage disease due to glycogen debranching enzyme deficiency
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=366
- Washington University, St. Louis: Neuromuscular Disease Center
  https://neuromuscular.wustl.edu/msys/glycogen.html#deb
Patient Support and Advocacy Resources

• Children's Cardiomyopathy Foundation
  https://dev.childrenscardiomyopathy.org/

• Metabolic Support UK
  https://www.metabolicSupportuk.org/

• Muscular Dystrophy Association: Debrancher Enzyme Deficiency
  https://www.mda.org/disease/metabolic-myopathies/types/cori-forbes-disease

• National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/forbes-disease/

• The Association for Glycogen Storage Disease (UK)

• The Association for Glycogen Storage Disease (US)
  https://www.agsdus.org/type-iii.php

• University of Kansas Medical Center Resource List
  http://www.kumc.edu/gec/support/glycogen.html

Clinical Information from GeneReviews

• Glycogen Storage Disease Type III
  https://www.ncbi.nlm.nih.gov/books/NBK26372

Scientific Articles on PubMed

• PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=^Glycogen+Storage+Disease+Type+III%5BMAJR%5D+AND+glycogen+storage+disease+type+III%5BTIAB%5D+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

• GLYCOGEN STORAGE DISEASE III
  http://omim.org/entry/232400
Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19299494  
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678930/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301788

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1194993

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20631546

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16705713

Reprinted from Genetics Home Reference:  

Reviewed: December 2014  
Published: February 11, 2020

Lister Hill National Center for Biomedical Communications  
U.S. National Library of Medicine  
National Institutes of Health  
Department of Health & Human Services